Traditional Chinese medicine composition for treating chronic atrophic gastritis and preparation method thereof

Abstract

The embodiment of the invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 5-15 parts of rhizoma atractylodis macrocephalae, 5-15 parts of ginger processed pinellia, 5-15 parts of bran-fried fructus aurantii, 5-25 parts of vinegar-processed rhizoma corydalis, 5-25 parts of cuttlebone, 4-8 parts of radix aucklandiae, 4-8 parts of fructus amomi, 6-18 parts of fried endothelium corneum gigeriae galli, 5-15 parts of fried malt, 5-15 parts of fried hawthorn, 5-15 parts of fried medicated leaven and 4-8 parts of honey-fried licorice root. The traditional Chinese medicine composition provided by the invention is scientific in raw material compatibility, simple and reasonable in matching by utilizing mutual cooperation of the raw materials, remarkable in effect in the aspect of improving / treating chronic atrophic gastritis, free of toxic and side effects, low in cost and relatively good in application prospect.

Description

Technical Field

[0001] The embodiments of the present invention relate to the technical field of traditional Chinese medicine, and particularly to a traditional Chinese medicine composition for treating chronic atrophic gastritis and a preparation method thereof. Background Art

[0002] Chronic atrophic gastritis is a chronic digestive system disease in which the gastric mucosa is repeatedly damaged, resulting in atrophy and reduction of gastric mucosal glands, with or without intestinal metaplasia. Its clinical manifestations include weight loss, loss of appetite, upper abdominal discomfort, pain, fullness, belching, anemia, etc. Its occurrence is related to factors such as Helicobacter pylori infection, diet, environment, autoimmunity, bile reflux, alcohol, age, etc. Traditional Chinese medicine classifies chronic atrophic gastritis into the categories of "epigastric pain", "stagnation and fullness", etc., and believes that chronic atrophic gastritis is a syndrome of deficiency in origin and excess in superficiality, with weakness of the spleen and stomach as its root and qi stagnation and blood stasis as its superficiality. Weakness of the spleen and stomach and blood stasis run through the entire pathogenesis of chronic atrophic gastritis. Currently, the treatment drugs mainly include antibiotics, proton pump inhibitors, acid suppressants, gastric mucosal protectants, etc., but there are certain adverse reactions and it is easy to relapse. Summary of the Invention

[0003] Therefore, the embodiments of the present invention provide a traditional Chinese medicine prescription for treating chronic atrophic gastritis and a preparation method thereof.

[0004] In order to achieve the above object, the embodiments of the present invention provide the following technical solutions:

[0005] According to the first aspect of the embodiments of the present invention, the present invention provides a traditional Chinese medicine composition for treating chronic atrophic gastritis, and the traditional Chinese medicine composition is composed of the following raw materials in parts by weight: 5 - 15 parts of Atractylodes macrocephala, 5 - 15 parts of Pinellia ternata processed with ginger, 5 - 15 parts of Fructus Aurantii stir-fried with bran, 5 - 25 parts of Corydalis yanhusuo processed with vinegar, 5 - 25 parts of Endoconcha Sepiae, 4 - 8 parts of Aucklandia lappa, 4 - 8 parts of Amomum villosum, 6 - 18 parts of Endothelium Corneum Gigeriae Galli stir-fried, 5 - 15 parts of Fructus Hordei Germinatus stir-fried, 5 - 15 parts of Fructus Crataegi stir-fried, 5 - 15 parts of Fructus Aspergi stir-fried, 4 - 8 parts of Radix Glycyrrhizae prepared.

[0006] Further, the traditional Chinese medicine composition is made from the following raw materials in parts by weight: 10 parts of Atractylodes macrocephala, 10 parts of Pinellia ternata processed with ginger, 10 parts of Fructus Aurantii stir-fried with bran, 15 parts of Corydalis yanhusuo processed with vinegar, 15 parts of Endoconcha Sepiae, 6 parts of Aucklandia lappa, 6 parts of Amomum villosum, 12 parts of Endothelium Corneum Gigeriae Galli stir-fried, 10 parts of Fructus Hordei Germinatus stir-fried, 10 parts of Fructus Crataegi stir-fried, 10 parts of Fructus Aspergi stir-fried, 6 parts of Radix Glycyrrhizae prepared.

[0007] According to the second aspect of the embodiments of the present invention, the present invention provides a preparation method of the above-mentioned traditional Chinese medicine composition for treating chronic atrophic gastritis. The raw materials are added to distilled water for soaking, boiled with strong fire and then decocted with slow fire. The medicinal liquid is filtered, and distilled water is added to the residue for decocting again. The two filtrates are combined, concentrated, and freeze-dried to constant weight.

[0008] Further, in the soaking process, the mass of distilled water is 8 - 10 times that of the total mass of raw materials, and the soaking conditions are: room temperature, 30 - 60 min.

[0009] Further, the time for slow fire decoction is 30 - 45 min.

[0010] Further, in the second decoction, the mass of distilled water is 1 - 1.5 times that of the residue mass.

[0011] Further, the temperature for concentration is 60 - 80 °C.

[0012] Further, calculated by the crude drug amount, the mass concentration of the concentrated ointment is 1.1 - 1.3 g / mL.

[0013] Further, the conditions for freeze - drying are: -50 to -80 °C, vacuum.

[0014] In the present invention, Atractylodes macrocephala is mainly used for less appetite due to spleen deficiency, abdominal distension and diarrhea, phlegm retention and dizziness and palpitation;

[0015] Pinellia ternata (Thunb.) Breit. var. pinellioides (Pritz.) Hsiao et K. M. Feng processed with ginger is pungent in taste and warm in nature, and is mainly used for arresting vomiting by lowering the adverse flow of qi, vomiting and nausea, and stuffiness and fullness in the chest and epigastrium;

[0016] Fructus Aurantii processed with bran regulates qi and relieves distension, and promotes qi movement and alleviates distension, and is used for qi stagnation in the chest and hypochondrium, fullness and pain, retention of food stagnation, and internal retention of phlegm - fluid;

[0017] Rhizoma Corydalis processed with vinegar is pungent, bitter, and warm in nature, and has the effects of promoting blood circulation and qi movement, regulating menstruation and relieving pain;

[0018] Endoconcha Sepiae is salty, astringent, and warm in nature, and belongs to the spleen and kidney meridians, and is used for treating gastric and duodenal ulcers and bleeding, etc.;

[0019] Radix Aucklandiae is pungent, bitter, and warm in nature, and has the functions of promoting qi movement to relieve pain, strengthening the spleen and promoting digestion, and is used for epigastric and abdominal distending pain, tenesmus after diarrhea, retention of food stagnation, and loss of appetite;

[0020] Fructus Amomi is pungent in taste and warm in nature, and belongs to the spleen, stomach, and kidney meridians, regulates qi and harmonizes the middle - jiao, and soothes the stomach, and is used for treating abdominal pain and distension, anorexia, and vomiting due to diaphragmatic obstruction;

[0021] Endothelium Corneum Gigeriae Galli processed by frying is sweet and flat in nature, and belongs to the spleen, stomach, small intestine, and bladder meridians, and is used for indigestion, spermatorrhea, night sweating, etc.;

[0022] Fructus Hordei Germinatus processed by frying is sweet and flat, and is used for retention of food stagnation, epigastric and abdominal distending pain, and less appetite due to spleen deficiency;

[0023] Fructus Crataegi processed by frying treats diarrhea and promotes digestion and appetizer, and has the effects of promoting blood circulation to remove stasis, preventing heatstroke, and lowering blood pressure;

[0024] Fructus Fermentatus processed by frying is warm in nature and belongs to the spleen and stomach meridians, and has the effects of promoting digestion and resolving food stagnation, strengthening the spleen and warming the stomach;

[0025] Zhigancao Decoction has the effects of tonifying qi and nourishing yin, and restoring yang and promoting the pulse circulation.

[0026] The embodiments of the present invention have the following advantages:

[0027] The traditional Chinese medicine composition provided by the present invention uses Atractylodes macrocephala, Pinellia ternata, stir-fried Fructus Aurantii, Corydalis yanhusuo, cuttlefish bone, Aucklandia lappa, Amomum villosum, stir-fried Endothelium Corneum Gigeriae Galli, stir-fried Fructus Hordei Germinatus, stir-fried Fructus Crataegi, stir-fried Massa Medicata Fermentata, and honey-roasted Licorice Root as raw materials. Among them, Atractylodes macrocephala and Pinellia ternata are the monarch drugs in the prescription, Aucklandia lappa and Amomum villosum are the ministerial drugs in the prescription, stir-fried Fructus Aurantii, Corydalis yanhusuo, cuttlefish bone, stir-fried Endothelium Corneum Gigeriae Galli, stir-fried Fructus Hordei Germinatus, stir-fried Fructus Crataegi, and stir-fried Massa Medicata Fermentata are the adjuvant drugs, and honey-roasted Licorice Root is the guiding drug. The compatibility of each raw material is scientific. Utilizing the mutual cooperation among the raw materials, the combination is simple and reasonable, and it has a remarkable effect in improving / treating chronic atrophic gastritis, with no toxic and side effects, low cost, and has good application prospects. Description of the Drawings

[0028] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the following will briefly introduce the drawings required for the description of the embodiments or the prior art. Obviously, the drawings in the following description are only exemplary, and for those of ordinary skill in the art, without creative efforts, other implementation drawings can also be obtained based on the provided drawings.

[0029] Figure 1 For the body weight of each group of rats (n = 8);

[0030] Figure 2 For the average food intake per rat per week of each group (n = 4); Note: Compared with the normal control group at the same time, # indicates a significant difference, P < 0.05; compared with the model group at the same time, * indicates a significant difference, P < 0.05;

[0031] Figure 3 For the gastric juice wide pH and total acidity of each group of rats (n = 8); Note: Compared with the normal control group at the same time, # indicates a significant difference, P < 0.05; compared with the model group at the same time, * indicates a significant difference, P < 0.05;

[0032] Figure 4 For the gastric coefficient of each group of rats (n = 8); Note: Compared with the normal control group at the same time, # indicates a significant difference, P < 0.05; compared with the model group at the same time, * indicates a significant difference, P < 0.05;

[0033] Figure 5 For the gastric mucosa pathology of each group of rats;

[0034] Figure 6Content of serum biomarkers in each group of rats (n = 6); Note: Compared with the normal control group at the same time, # indicates a significant difference, P < 0.05; compared with the model group at the same time, * indicates a significant difference, P < 0.05. Specific implementation manners

[0035] The following specific embodiments illustrate the implementation manners of the present invention. Those skilled in the art can easily understand other advantages and effects of the present invention from the content disclosed in this specification. Obviously, the described embodiments are part of the embodiments of the present invention, rather than all of them. All other embodiments obtained by those of ordinary skill in the art based on the embodiments of the present invention without creative efforts belong to the scope of protection of the present invention.

[0036] Atractylodes macrocephala, Pinellia ternata processed with ginger, Fructus Aurantii stir-fried with bran, Corydalis yanhusuo processed with vinegar, Sepia seu cuttlebone, Aucklandia lappa, Amomum villosum, Endothelium corneum gigeriae galli stir-fried, Fructus Hordei Germinatus stir-fried, Fructus Crataegi stir-fried, Massa Medicata Fermentata stir-fried, and Glycyrrhiza uralensis preparata were all purchased from Bozhou Shanan Hall Chinese Herbal Pieces Co., Ltd.

[0037] Example 1

[0038] This example provides a Qi-regulating and stomach-regulating formula, and its raw materials are: 10 parts of Atractylodes macrocephala, 10 parts of Pinellia ternata processed with ginger, 10 parts of Fructus Aurantii stir-fried with bran, 15 parts of Corydalis yanhusuo processed with vinegar, 15 parts of Sepia seu cuttlebone, 6 parts of Aucklandia lappa, 6 parts of Amomum villosum, 12 parts of Endothelium corneum gigeriae galli stir-fried, 10 parts of Fructus Hordei Germinatus stir-fried, 10 parts of Fructus Crataegi stir-fried, 10 parts of Massa Medicata Fermentata stir-fried, and 6 parts of Glycyrrhiza uralensis preparata.

[0039] Its preparation method includes: weighing the above raw materials according to the weight parts, immersing them in 10 times the amount of distilled water for 45 minutes, boiling with strong fire and then turning to slow fire for decocting for 45 minutes, filtering the medicinal liquid, adding the same amount of distilled water to the residue and decocting again once, combining the two filtrates, concentrating the filtrate in a 75 °C water bath, concentrating it into an ointment with a mass concentration of 1.2 g / mL (calculated based on the raw drug amount), freeze-drying to constant weight under vacuum conditions at -50 to -80 °C, and storing it at 4 °C for later use.

[0040] Example 2

[0041] This example provides a Qi-regulating and stomach-regulating formula, and its raw materials are: 6 parts of Atractylodes macrocephala, 12 parts of Pinellia ternata processed with ginger, 10 parts of Fructus Aurantii stir-fried with bran, 20 parts of Corydalis yanhusuo processed with vinegar, 12 parts of Sepia seu cuttlebone, 4 parts of Aucklandia lappa, 8 parts of Amomum villosum, 15 parts of Endothelium corneum gigeriae galli stir-fried, 10 parts of Fructus Hordei Germinatus stir-fried, 12 parts of Fructus Crataegi stir-fried, 6 parts of Massa Medicata Fermentata stir-fried, and 4 parts of Glycyrrhiza uralensis preparata. Its preparation method is the same as that of Example 1.

[0042] Example 3

[0043] This embodiment provides a formula for regulating qi and harmonizing the stomach, and its raw materials are: 12 parts of Atractylodes macrocephala, 8 parts of Pinellia ternata processed with ginger, 12 parts of Fructus Aurantii stir-fried with bran, 12 parts of Corydalis yanhusuo processed with vinegar, 5-15 parts of Endoconcha Sepiae, 6 parts of Aucklandia lappa, 4 parts of Amomum villosum, 10 parts of Endothelium Corneum Gigeriae Galli stir-fried, 12 parts of Fructus Hordei Germinatus stir-fried, 8 parts of Fructus Crataegi stir-fried, 8 parts of Fructus Aspergi stir-fried, and 6 parts of Glycyrrhiza uralensis processed with honey. Its preparation method is the same as that of Example 1.

[0044] Test Example 1

[0045] I. Experimental materials

[0046] 1. Materials and reagents

[0047] Weifuchun capsules were purchased from Hangzhou Huqingyutang Pharmaceutical Co., Ltd. N-Methyl-N'-nitro-N-nitrosoguanidine (CAS No. 70-25-7, purity ≥ 95%) was purchased from Shanghai Macklin Biochemical Co., Ltd. ELISA kits were all purchased from Beinlai Biotechnology Co., Ltd. The formula for regulating qi and harmonizing the stomach: Example 1.

[0048] 2. Experimental animals

[0049] Healthy male SD rats, 6 weeks old, with a body weight of about 200 ± 20 g, were purchased from SPF (Beijing) Biotechnology Co., Ltd. and raised in the Animal Experiment Center of the School of Pharmacy of Shihezi University. The temperature of the breeding environment was always maintained at 20-25 °C, and the relative humidity was controlled at 50%-60%. The light and darkness alternated every day for 12 hours. After 1 week of adaptive feeding, grouping and establishment of chronic atrophic gastritis models were carried out.

[0050] II. Experimental methods

[0051] 1. Modeling and drug administration of chronic atrophic gastritis rats

[0052] After 1 week of adaptive feeding of healthy male SD rats, they were divided into a normal group (n = 8) and a model group (n = 40) by the random number table method. Rats in the normal group were given regular diet and water, while rats in the model group were given N-methyl-N'-nitro-N-nitrosoguanidine water (170 μg / mL) to drink every day and combined with irregular feeding (alternate days of feeding), and at the same time, N-methyl-N'-nitro-N-nitrosoguanidine water (1 mL / 100 g) was intragastrically administered every other day for 10 consecutive weeks to construct a chronic atrophic gastritis rat model. The successful sign of model construction was that HE staining showed atrophy and reduction of gastric mucosal glands accompanied by infiltration of inflammatory cells. Subsequently, the rats in the model group were randomly divided into a model group (n = 8), a positive drug Weifuchun group (n = 8, 0.43 g / kg), a low-dose formula for regulating qi and harmonizing the stomach group (n = 8, 6 g / kg), a medium-dose formula for regulating qi and harmonizing the stomach group (n = 8, 12 g / kg), and a high-dose formula for regulating qi and harmonizing the stomach group (n = 8, 24 g / kg), and the corresponding drugs were intragastrically administered continuously for 4 weeks. During this period, rats in the model group and the normal group were intragastrically administered with the same volume of distilled water.

[0053] 2. Measurement of rat body weight

[0054] Measure and record the body weights of rats in each group throughout the experiment, and analyze the changes in body weights of rats in each group.

[0055] 3. Measurement of rat food intake

[0056] After starting the drug administration, record the food intake of each rat every day, calculate and compare the differences in the average food intake of rats in each group.

[0057] 4. Measurement of gastric juice pH in rats

[0058] After the drug administration is completed, collect the gastric contents of rats, centrifuge (at 4°C, 13000 rpm, for 10 min) to obtain gastric juice, use a wide-range pH test paper method to measure the pH value of gastric juice, and use an acid-base titration method to measure the total acidity of gastric juice.

[0059] 5. Measurement of rat gastric coefficient

[0060] After the drug administration is completed, weigh the body weight of the rats, anesthetize the rats, weigh and retain the gastric tissues of the rats, and finally calculate the gastric coefficient of the rats. Among them, gastric coefficient = gastric weight / rat body weight × 100%.

[0061] 6. Histopathological determination of rat gastric mucosa

[0062] After the experiment is completed, fix the rat gastric tissues with 4% paraformaldehyde, then dehydrate, clear, embed in paraffin and section to make tissue sections, perform HE staining, and observe the histopathological changes of the gastric tissues. Specifically observe: whether there are lesions in the gastric mucosa structure; whether the intrinsic glands are atrophied and reduced; whether the gland arrangement is disordered; whether there are goblet cells, inflammatory cells, etc.

[0063] 7. Determination of rat serum biomarkers

[0064] After the experiment is completed, collect the whole blood of rats, centrifuge (at 3500 rpm, for 15 min) to obtain serum, balance the kit at room temperature for 20 min, add standard products and samples with different concentrations respectively, and strictly operate according to the kit instructions. Zero with the blank well, and measure the absorbance values (OD values) of each well in sequence at a wavelength of 450 nm; according to the standard product concentration and OD value, calculate the regression equation of the standard curve, and calculate the expression levels of GAS-17, PGI, PGI / PGII, and IL-1β in the serum of rats in each group according to the regression equation.

[0065] 8. Data processing

[0066] All data are expressed in the form of mean ± standard deviation, and one-way ANOVA is performed using SPSS 27.0 statistical software. P < 0.05 is considered that there is a statistically significant difference between the two groups of experimental data.

[0067] III. Experimental Results

[0068] 1. Effect of the Formula for Regulating Qi and Harmonizing the Stomach on the Body Weight of Rats with Chronic Atrophic Gastritis

[0069] As Figure 1 shown, during the experiment, the body weight of rats in the normal control group (Control) gradually increased with a large growth rate, while the growth rate of the body weight of rats with chronic atrophic gastritis model (Model) was small, indicating that the establishment of the chronic atrophic gastritis model was successful. After drug intervention, compared with the model group, the growth rate of the body weight of rats in each dose group of the Formula for Regulating Qi and Harmonizing the Stomach increased to varying degrees. The growth rate of the body weight of rats in the low-dose group of the Formula for Regulating Qi and Harmonizing the Stomach (LQHWP-L) was smaller than that of other groups, while the therapeutic effect of the body weight of rats in the medium-dose group of the Formula for Regulating Qi and Harmonizing the Stomach (LQHWP-M) was similar to that of the positive drug Weifuchun group (WFC). The improvement effect of the body weight of rats in the high-dose group of the Formula for Regulating Qi and Harmonizing the Stomach (LQHWP-H) was significant (P<0.05), indicating that the therapeutic effect of the Formula for Regulating Qi and Harmonizing the Stomach may have a certain dose-dependence.

[0070] 2. Effect of the Formula for Regulating Qi and Harmonizing the Stomach on the Food Intake of Rats with Chronic Atrophic Gastritis

[0071] As Figure 2 can be seen, after drug intervention, compared with the normal control group, the food intake of rats in the model group of the Formula for Regulating Qi and Harmonizing the Stomach decreased. Compared with the model group, the food intake of each administration group increased. The food intake of the low-dose group of the Formula for Regulating Qi and Harmonizing the Stomach increased, but there was no statistical significance. The improvement effects of the medium- and high-dose groups of the Formula for Regulating Qi and Harmonizing the Stomach were significant, and the improvement effect of the high-dose group of the Formula for Regulating Qi and Harmonizing the Stomach on the reduction of food intake of rats with chronic atrophic gastritis was the most significant.

[0072] 3. Effect of the Formula for Regulating Qi and Harmonizing the Stomach on the Gastric Juice pH of Rats with Chronic Atrophic Gastritis

[0073] As Figure 3 shown, the gastric juice pH value of rats in the normal control group was acidic. Compared with the normal control group, the gastric juice pH value of rats in the model group increased significantly and the total gastric acidity decreased significantly (P<0.01); after intervention with low, medium, and high doses of the Formula for Regulating Qi and Harmonizing the Stomach, the gastric juice pH value of rats decreased significantly and the total gastric acidity increased significantly (P<0.05).

[0074] 4. Effect of the Formula for Regulating Qi and Harmonizing the Stomach on the Gastric Coefficient of Rats

[0075] After recording the weights of rats and their gastric tissues at the end of the experiment, as Figure 4As shown, compared with the normal control group, the gastric coefficient of the rats in the model group increased significantly (P<0.05). Compared with the model group, the Liqi Hewei Formula could reduce the gastric coefficient of the rats, and the medium-dose group of the Liqi Hewei Formula had the most significant reducing effect (P<0.05), while the other treatment groups had improvement effects but without statistical significance.

[0076] 5. Effects of the Liqi Hewei Formula on the pathological state of gastric mucosa in rats

[0077] Reduction of gastric mucosal gland atrophy is a hallmark feature of chronic atrophic gastritis. As Figure 5 shown, the gastric mucosal structure of the rats in the normal group was intact and the thickness was normal, and the glands were arranged orderly. Compared with the normal group, the gastric mucosal glands of the rats in the model group showed atrophy and reduction, disordered arrangement, and there was an infiltration of inflammatory cells. Compared with the model group, each dose group of the Liqi Hewei Formula could improve the above situation to varying degrees, and the high-dose group of the Liqi Hewei Formula had the best improvement effect.

[0078] 6. Effects of the Liqi Hewei Formula on serum biomarkers in rats

[0079] Gastrin-17 (GAS-17) is a key gastrointestinal hormone secreted by G cells in the gastric antrum and the upper part of the small intestine, and its main biological function is to stimulate the secretion of fundic glands in the stomach. The research results are as Figure 6 shown in Figure -A. Compared with the normal group, the content of GAS-17 in the model group increased, while the content in each dose group of the Liqi Hewei Formula decreased. At present, pepsinogen has become a crucial clinical measure for diagnosing chronic atrophic gastritis and even gastric cancer. As Figure 6 shown in Figure B-C, compared with the normal group, the contents of pepsinogen I (PGI) and pepsinogen I / pepsinogen II (PGI / PGII) in the serum of the rats in the model group decreased. Compared with the model group, after treatment with the Liqi Hewei Formula, the contents of the two in the serum of the rats could be reversed, and the improvement effect of the high-dose group of the Liqi Hewei Formula was significant. Interleukin-1β (IL-1β) is a key pro-inflammatory factor in chronic atrophic gastritis and is closely related to the severity of gastric atrophy. As Figure 6 shown in Figure -D, compared with the normal group, the IL-1β in the serum of the rats in the model group increased significantly. Compared with the model group, the content of IL-1β in the treatment group of the Liqi Hewei Formula decreased significantly, indicating the successful establishment of the chronic atrophic gastritis rat model. At the same time, the Liqi Hewei Formula could reverse the increase of the pro-inflammatory factor IL-1β in the serum of chronic atrophic gastritis rats.

[0080] In summary, this invention started from the traditional Chinese medicine prescription of the Liqi Hewei Formula to explore its effects on the body weight, food intake, gastric coefficient, gastric juice pH, pathological state of gastric mucosa and its serum biomarkers in rats induced by N-methyl-N'-nitro-N-nitrosoguanidine. The results showed that the Liqi Hewei Formula could reverse the above indicators to varying degrees and thus improve chronic atrophic gastritis.

[0081] Although the present invention has been described in detail above with general descriptions and specific embodiments, some modifications or improvements can be made to it based on the present invention, which will be obvious to those skilled in the art. Therefore, these modifications or improvements made without departing from the spirit of the present invention fall within the scope of protection required by the present invention.

Claims

1. A traditional Chinese medicine composition for treating chronic atrophic gastritis, characterized in that, The traditional Chinese medicine composition is composed of the following raw materials in parts by weight: Atractylodes macrocephala 5 - 15 parts, Pinellia ternata processed with ginger 5 - 15 parts, Fructus Aurantii stir-fried with bran 5 - 15 parts, Corydalis yanhusuo processed with vinegar 5 - 25 parts, Sepia seu cuttlefish bone 5 - 25 parts, Aucklandia lappa 4 - 8 parts, Amomum villosum 4 - 8 parts, Endothelium corneum gigeriae galli stir-fried 6 - 18 parts, Fructus Hordei Germinatus stir-fried 5 - 15 parts, Fructus Crataegi stir-fried 5 - 15 parts, Massa Medicata Fermentata stir-fried 5 - 15 parts, Glycyrrhiza uralensis processed with honey 4 - 8 parts.

2. The traditional Chinese medicine composition for treating chronic atrophic gastritis according to claim 1, wherein The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: Atractylodes macrocephala 10 parts, Pinellia ternata processed with ginger 10 parts, Fructus Aurantii stir-fried with bran 10 parts, Corydalis yanhusuo processed with vinegar 15 parts, Sepia seu cuttlefish bone 15 parts, Aucklandia lappa 6 parts, Amomum villosum 6 parts, Endothelium corneum gigeriae galli stir-fried 12 parts, Fructus Hordei Germinatus stir-fried 10 parts, Fructus Crataegi stir-fried 10 parts, Massa Medicata Fermentata stir-fried 10 parts, Glycyrrhiza uralensis processed with honey 6 parts.

3. The preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis according to claim 1, characterized in that, Add the raw materials to distilled water for soaking, bring to a boil over high heat and then turn to low heat for decocting. Filter the decoction liquid, add distilled water to the residue for decocting again, combine the two filtrates, concentrate, and freeze-dry to constant weight.

4. The preparation method according to claim 3, characterized in that, In the above soaking process, the mass of distilled water is 8 - 10 times the total mass of the raw materials, and the soaking conditions are: room temperature, 30 - 60 min.

5. The preparation method according to claim 3, characterized in that, The time for decocting over low heat is 30 - 45 min.

6. The preparation method according to claim 3, wherein In the above-mentioned second decocting, the mass of distilled water is 1 - 1.5 times the mass of the residue.

7. The preparation method according to claim 3, characterized in that The temperature for concentration is 60 - 80 °C.

8. The preparation method according to claim 3, wherein Calculated by the crude drug amount, the mass concentration of the concentrated ointment is 1.1 - 1.3 g / mL.

9. The preparation method according to claim 3, characterized in that, The conditions for freeze-drying are: -50 to -80 °C, vacuum.

Images